Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5525438 | 0.93 | ALDH1A1 (0.45) | HTTKMT2AMAPK1LMNAMEN1 | |
| SCHEMBL5533348 | 0.92 | HTT (0.42) | HTTKMT2AMAPK1LMNAMEN1 | |
| SCHEMBL5530135 | 0.89 | KMT2A (0.40) | HTTKMT2AMAPK1LMNAMEN1 | |
| SCHEMBL5525609 | 0.88 | ALDH1A1 (0.41) | HTTKMT2AMAPK1LMNAMEN1 | |
| SCHEMBL5528707 | 0.83 | STAT3 (0.46) | HTTKMT2AMAPK1LMNAMEN1 | |
| SCHEMBL5919414 | 0.82 | CYP3A4 (0.42) | KMT2AMAPK1LMNAMEN1ALDH1A1 | |
| SCHEMBL5529474 | 0.81 | HTT (0.40) | HTTKMT2AMAPK1LMNAMEN1 | |
| SCHEMBL14417318 | 0.81 | KDM4E (0.42) | HTTKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL5526755 | 0.81 | HPGD (0.45) | HTTALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL5528957 | 0.81 | CYP3A4 (0.40) | KMT2ALMNAMEN1ALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1230937-B1 | A thermoplastic composition of polyurethane for orthopaedic applications | RUNLITE S A (BE) | 2006-11-02 | — | — | EP | claimed |
| EP-1230937-A1 | A thermoplastic composition of polyurethane for orthopaedic applications | Runlite S.A. (BE) | 2002-08-14 | — | — | EP | claimed |
| US-20070213339-A1 | Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213339-A1 | Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213339-A1 | Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-13 | — | — | US | disclosed |
| EP-1732897-A1 | QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDITIONS | Bayer Pharmaceuticals Corporation (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1230937-B1 | A thermoplastic composition of polyurethane for orthopaedic applications | RUNLITE S A (BE) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005097752-A1 | QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDITIONS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-10-20 | — | — | WO | disclosed |
| EP-1230937-A1 | A thermoplastic composition of polyurethane for orthopaedic applications | Runlite S.A. (BE) | 2002-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213339-A1 | Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions | TP53, RB1, HRAS | HTT 3021/4885KMT2A 2389/4885MAPK1 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.